SAINT LAURENT,, Oct. 17, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) today announced that it intends to distribute  units (the “Units”), each Unit consisting of one share of common stock and one half of one warrant, each whole warrant to purchase one share of common stock in the United States and the Canadian provinces of Alberta, British Columbia, Manitoba, Ontario and Quebec (the “Offering”) by means of a prospectus supplement to the U.S. registration statement on Form S-3 (File No. 333-227498) which was declared effective on October 15, 2018 (the “Registration Statement”), and a Canadian MJDS prospectus supplement to the Canadian MJDS short-form base shelf prospectus dated October 15, 2018 (the “MJDS Prospectus”). The number of Units to be distributed, the price of each Unit and the exercise price of each whole warrant will be determined in the context of the market with final terms to be determined at the time of pricing. H.C. Wainwright & Co. is acting as the exclusive U.S. placement agent. Echelon Wealth Partners Inc. is acting as the exclusive placement agent for the Units offered in Canada.

Before investing, you should read the prospectus supplement as well as the MJDS Prospectus and the Registration Statement and other documents the Company has filed with the United States Securities and Exchange Commission and the Canadian securities regulators for more complete information about the Company and this Offering. 

A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed Offering has been filed with the SEC and the Canadian securities regulators. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered in the U.S. may also be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3^rd Floor, New York, NY 10022, by calling (646) 975-6996 or by emailing placements@hcwco.com, and in Canada from Echelon Wealth Partners Inc., 1 Adelaide Street East, Suite 2100, Toronto, ON M5C 2V9, by calling (416) 479-7370 or emailing ecm@echelonpartners.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus are also be available on the SEC's website at http://www.sec.gov and under the Company’s profile on www.sedar.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, Units, warrants or shares of common stock of the Company in any state or province in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state, province, or other jurisdiction.    

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the Company can be found at www.intelgenx.com.

Forward-Looking Information and Statements

This document may contain forward-looking information or forward-looking statements within the meaning of applicable U.S. and Canadian securities laws. These statements are statements that are not purely historical. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, the factors discussed under the heading “Risk Factors” in the Registration Statement, the prospectus supplement and in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Although the Company believes that the expectations and assumptions on which Forward-Looking Information is based are reasonable, readers of this press release are cautioned not to rely unduly on this Forward-Looking Information since no assurance can be given that they will prove to be correct. The Company does not undertake any obligation to update or revise any Forward-Looking Information, whether as a result of events or circumstances occurring after the date of this press release, unless so required by legislation.

For more information, please contact:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com

OR

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Technologies Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.